Cardiff Oncology Appoints Dr. Roger Sidhu as New Chief Medical Officer, Sets Timing for Next CRDF-004 Trial Update in RAS-mutated mCRC

Cardiff Oncology appoints Dr. Roger Sidhu as Chief Medical Officer, succeeding Dr. Fairooz Kabbinavar. Dr. Sidhu brings over 20 years of oncology leadership experience, with notable achievements in mCRC clinical trials. The company will present new clinical data from the CRDF-004 trial in late July 2025.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company, has announced the appointment of Dr. Roger Sidhu as its Chief Medical Officer (CMO), succeeding Dr. Fairooz Kabbinavar. Dr. Sidhu brings over two decades of oncology leadership experience, including a strong track record in clinical trials for metastatic colorectal cancer (mCRC). The company will also present new clinical data from its CRDF-004 trial in late July 2025.

Dr. Sidhu, who most recently served as the CMO and acting CEO at Treadwell Therapeutics, has extensive experience in oncology research, development, and regulatory strategy. He has led multiple phase 3 clinical trials and has a proven track record of advancing innovative therapies through late-stage clinical development. In mCRC, he led trials of panitumumab (Vectibix®) in monotherapy and combination with chemotherapy, resulting in global approvals. Dr. Sidhu has also contributed to the scientific understanding of RAS biology and therapeutics in mCRC, publishing work in peer-reviewed journals including the New England Journal of Medicine.

Dr. Sidhu succeeds Dr. Kabbinavar, who will remain with the company in an advisory role. The appointment of Dr. Sidhu comes as Cardiff Oncology prepares to share additional clinical data from its lead program in RAS-mutated mCRC on July 29, 2025. The company will host a conference call and live webcast to present this data, with details available on the company's website [1].

Cardiff Oncology's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in various cancer indications. The company's broader development strategy aims to target tumor vulnerabilities to overcome treatment resistance and deliver superior clinical benefit compared to SoC alone.

The appointment of Dr. Sidhu is part of Cardiff Oncology's ongoing efforts to advance its pipeline of oncology therapies. The company's stock options were granted to Dr. Sidhu as an inducement to join, with an exercise price of $3.86 per share [1].

Investors and financial professionals are advised to review the company's Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission for a complete list of risks and uncertainties [1].

References:
[1] https://finance.yahoo.com/news/cardiff-oncology-appoints-dr-roger-200500215.html